Sugi Predict

Sugi Predict / Compounds / SCHEMBL30980574

SCHEMBL30980574

SCHEMBL30980574

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1c1cc(COCCOCCNC(=O)NCCCC(CCCNC(=O)NCCOCCOCc2cc([C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)on2)(CCCNC(=O)NCCOCCOCc2cc([C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)on2)NC(=O)OCc2ccccc2)no1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ HRAS P01112 1/20 0.37
▸ LMNA P02545 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ OGA O60502 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980722 0.86 OGA (0.35) OGA
SCHEMBL30980620 0.84 HRAS (0.39) HRASLMNASMN1; SMN2OGA
SCHEMBL30980659 0.80 LMNA (0.41) HRASLMNASMN1; SMN2
SCHEMBL31078937 0.77 HRAS (0.38) HRASLMNASMN1; SMN2OGA
SCHEMBL30980664 0.76 LMNA (0.41) HRASLMNASMN1; SMN2
SCHEMBL30980660 0.76 MAPK1 (0.38) HRAS
SCHEMBL30980607 0.72 MDK (0.40) HRASLMNASMN1; SMN2OGA
SCHEMBL24239904 0.72 LMNA (0.52) HRASLMNASMN1; SMN2
SCHEMBL30980624 0.71 MAPK1 (0.52) HRASLMNASMN1; SMN2
SCHEMBL30980474 0.70 PTPN1 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback